Misplaced Pages

Funobactam

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Funobactam
Clinical data
Other namesXNW-4107
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • -1,3,4-oxadiazol-2-yl]-7-oxospirooctane-4,1'-cyclopropane]-6-yl] sulfate
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC13H17N7O6S
Molar mass399.38 g·mol
3D model (JSmol)
SMILES
  • C1CC12C(N3C2N(C3=O)OS(=O)(=O))C4=NN=C(O4)5C=C(N5)N
InChI
  • InChI=1S/C13H17N7O6S/c14-11-15-4-6(16-11)9-17-18-10(25-9)7-3-13(1-2-13)8-5-19(7)12(21)20(8)26-27(22,23)24/h6-8H,1-5H2,(H3,14,15,16)(H,22,23,24)/t6-,7-,8-/m0/s1
  • Key:GRRBXZJDEZJMHA-FXQIFTODSA-N

Funobactam is an investigational new drug that is being evaluated for the treatment of hospital-acquired bacterial pneumonia. It is a β-lactamase inhibitor.

References

  1. Clinical trial number NCT05204563 for "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (REITAB-2)" at ClinicalTrials.gov
  2. Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, et al. (June 2024). "Unveiling the Secrets of Acinetobacter baumannii: Resistance, Current Treatments, and Future Innovations". International Journal of Molecular Sciences. 25 (13): 6814. doi:10.3390/ijms25136814. PMC 11241693. PMID 38999924.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: